Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
May 16, 2022 16:15 ET
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE)...
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
May 11, 2022 08:30 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in...
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
March 31, 2022 16:15 ET
|
Interpace Biosciences, Inc.
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior...
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
February 22, 2022 09:00 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the...
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
January 28, 2022 19:35 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was...
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering
January 12, 2022 16:41 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully...
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
January 03, 2022 17:07 ET
|
Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...
Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results
November 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly...
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans
November 02, 2021 16:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a...
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions
October 28, 2021 08:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...